- Home
- MGIC vs TGTX Comparison
MGIC vs TGTX Comparison
Compare MGIC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- TGTX
- Stock Information
- Founded
- MGIC 1983
- TGTX 1993
- Country
- MGIC Israel
- TGTX United States
- Employees
- MGIC N/A
- TGTX N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- TGTX Health Care
- Exchange
- MGIC Nasdaq
- TGTX Nasdaq
- Market Cap
- MGIC 1.0B
- TGTX 4.2B
- IPO Year
- MGIC 1991
- TGTX 1995
- Fundamental
- Price
- MGIC $20.17
- TGTX $31.99
- Analyst Decision
- MGIC Buy
- TGTX Strong Buy
- Analyst Count
- MGIC 2
- TGTX 4
- Target Price
- MGIC $18.00
- TGTX $42.50
- AVG Volume (30 Days)
- MGIC 41.3K
- TGTX 2.0M
- Earning Date
- MGIC 08-13-2025
- TGTX 11-03-2025
- Dividend Yield
- MGIC 2.83%
- TGTX N/A
- EPS Growth
- MGIC 16.93
- TGTX N/A
- EPS
- MGIC 0.78
- TGTX 0.36
- Revenue
- MGIC $584,528,000.00
- TGTX $454,069,000.00
- Revenue This Year
- MGIC $11.11
- TGTX $82.58
- Revenue Next Year
- MGIC $6.83
- TGTX $44.99
- P/E Ratio
- MGIC $26.09
- TGTX $87.91
- Revenue Growth
- MGIC 11.98
- TGTX 30.96
- 52 Week Low
- MGIC $10.42
- TGTX $21.16
- 52 Week High
- MGIC $22.00
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- MGIC 51.75
- TGTX 52.24
- Support Level
- MGIC N/A
- TGTX N/A
- Resistance Level
- MGIC $20.80
- TGTX $32.56
- Average True Range (ATR)
- MGIC 0.46
- TGTX 1.06
- MACD
- MGIC -0.71
- TGTX -0.79
- Stochastic Oscillator
- MGIC 96.74
- TGTX 95.51
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.